key: cord-0878850-jf90g80y
authors: Canal, Berta; McClure, Allison W.; Curran, Joseph F.; Wu, Mary; Ulferts, Rachel; Weissmann, Florian; Zeng, Jingkun; Bertolin, Agustina P.; Milligan, Jennifer C.; Basu, Souradeep; Drury, Lucy S.; Deegan, Tom; Fujisawa, Ryo; Roberts, Emma L.; Basier, Clovis; Labib, Karim; Beale, Rupert; Howell, Michael; Diffley, John F.X
title: Identifying SARS-CoV-2 Antiviral Compounds by Screening for Small Molecule Inhibitors of Nsp14/nsp10 Exoribonuclease
date: 2021-04-08
journal: bioRxiv
DOI: 10.1101/2021.04.07.438812
sha: 5b5d496d81115abd0c46612ac589aba59d4a15c5
doc_id: 878850
cord_uid: jf90g80y

SARS-CoV-2 is a coronavirus that emerged in 2019 and rapidly spread across the world causing a deadly pandemic with tremendous social and economic costs. Healthcare systems worldwide are under great pressure, and there is urgent need for effective antiviral treatments. The only currently approved antiviral treatment for COVID-19 is remdesivir, an inhibitor of viral genome replication. SARS-CoV-2 proliferation relies on the enzymatic activities of the non-structural proteins (nsp), which makes them interesting targets for the development of new antiviral treatments. With the aim to identify novel SARS-CoV-2 antivirals, we have purified the exoribonuclease/methyltransferase (nsp14) and its cofactor (nsp10) and developed biochemical assays compatible with high-throughput approaches to screen for exoribonuclease inhibitors. We have screened a library of over 5000 commercial compounds and identified patulin and aurintricarboxylic acid (ATA) as inhibitors of nsp14 exoribonuclease in vitro. We found that patulin and ATA inhibit replication of SARS-CoV-2 in a VERO E6 cell-culture model. These two new antiviral compounds will be valuable tools for further coronavirus research as well as potentially contributing to new therapeutic opportunities for COVID-19.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the human coronavirus disease 19 [1, 2] . The large number of infections and the severe and long-term consequences of COVID-19 have greatly burdened healthcare systems worldwide [3] [4] [5] [6] . Lockdowns and "stay-at-home" orders have been the only effective strategy to cut infections around the world, but they come with major societal and economic costs.

Long term solutions to the health and economic crises will rely on our ability to properly monitor the evolution of the pandemic, on the effectiveness of novel vaccines, and on the development of new antiviral treatments to prevent the loss of further lives until we are able to control infections globally [7, 8] .

Coronaviruses represent a threat to human health: in addition to SARS-CoV-2, two other coronaviruses, SARS-CoV-1 and MERS-CoV, have been responsible for severe human diseases this century [9] . Despite this, there is a lack of antiviral treatments for diseases caused by coronaviruses [10, 11] . Currently, the only antiviral agent approved by regulatory agencies for treatment of COVID-19 is remdesivir, a delayed chain-terminator nucleotide analogue that impairs SARS-CoV-2 viral replication [12] . However, the WHO-funded Solidarity trial failed to identify increased survival or reduced hospitalisation time in patients treated with remdesivir, casting doubt on its effectiveness in treating COVID-19 [13] [14] [15] [16] .

SARS-CoV-2 is a betacoronavirus of the order Nidovirales with a positive-sense RNA strand

To obtain sufficient quantities of active SARS-CoV-2 nsp14 exonuclease and nsp10 cofactor proteins for high-throughput screening, we tested a variety of protein tagging and expression strategies (Supplementary Table S1 and S2). All protein purifications involved an initial step based on an affinity tag followed by at least one other purification step (Supplementary   Table S3 ). We first expressed and purified nsp14 and nsp10 individually from Escherichia coli (E. coli or ec) and baculovirus infected Sf9 insect cells (sf) ( Figure 1A ).

We tested nsp14 exoribonuclease activity using a double-strand RNA (dsRNA) substrate with 7-nucleotide overhangs on both the 5' and 3' ends, with one strand 5' labelled with Cy5 (Cy5-dsRNA substrate) ( Figure 1B) . Reaction products were analysed on denaturing TBEurea polyacrylamide gels, where generation of faster migrating products indicates enzymatic cleavage of the Cy5-dsRNA substrate. We did not observe cleavage of the Cy5-substrate in the presence of individual nsp14(ec) and 3xFlag-6His-nsp14(sf) proteins alone ( Figure 1C ).

As shown previously [26] , addition of increasing amounts of the cofactor nsp10 (nsp10-6His-3xFlag(sf)) promoted the nuclease activity of nsp14 and, to a lesser extent, of 3xFlag-6His-nsp14 ( Figure 1D ). In contrast to other reports [26] , N-terminal tagged nsp10(ec) was unable to stimulate nsp14 activity at similar concentrations ( Figure 1D ).

We also purified co-expressed nsp14/10 complexes ( Figure 1E ). When the nsp14 subunit harboured the affinity tag for purification, the nsp10 subunit was less abundant and, reciprocally, when the nsp10 subunit harboured the affinity tag for purification, the nsp14 subunit was less abundant, suggesting that the complex formed by nsp14 and nsp10 is not stable stoichiometrically. Nevertheless, both nsp14/10 complexes co-expressed in E.coli or insect cells showed nuclease activity comparable to the single nsp14 + nsp10-6His-3xFlag proteins ( Figure 1F and 1G).

To study nsp14/10 exonuclease activity and perform a high-throughput screen, we developed a fluorescence-based assay using the intercalating Quant-it TM RiboGreen RNA reagent ( Figure 2A) . We tested dilutions of RiboGreen against the Cy5-dsRNA substrate, and found a wide linear range of fluorescence using a 1/400 dilution of RiboGreen ( Figure   2B and Supplementary Figure S1 ). RiboGreen fluorescence decayed after prolonged incubation in our reaction buffers ( Figure 2C ), so all subsequent experiments were analysed immediately after RiboGreen addition. To evaluate nsp14/10 exonuclease activity with the RiboGreen assay, we took the samples shown in Figure 1F and incubated them with RiboGreen. As predicted, RiboGreen fluorescence decreased with increasing amounts of nsp14/10 consistent with exoribonuclease activity ( Figure 2D ).

The untagged subunit in the nsp14/10 complex preparations tended to be substoichiometric ( Figure 1E ), and relatively high amounts of nsp10 were required to stimulate nsp14 ( Figure   1D ), suggesting that the nsp14/10 complex might not be stable. We therefore wondered if direct fusion of nsp10 to nsp14 would generate a more active enzyme. A similar strategy was successful with the SARS-CoV-1 proteins nsp12/7/8, which purify as a more active polymerase complex when nsp7 and nsp8 are fused together with a short linker [34] . To test this, we expressed nsp14-linker-nsp10 (nsp14-10) and nsp10-linker-nsp14 (nsp10-14) fusion proteins in E. coli ( Figure 3A and 3B). The nsp10-14 fusion cleaved the Cy5-dsRNA substrate in both the gel and RiboGreen assays ( Figure 3C ). Titration of nsp10-14 fusion protein showed high exonuclease activity with as little as 1-3 nM of protein compared to about 200 nM needed for the nsp14/10 co-expressed complex ( Figure 3D ). The nsp14-10 fusion protein also showed high exonuclease activity ( Figure 3D ). To avoid any interference between Cy5 and RiboGreen, we then titrated the nsp10-14 fusion in the presence of an unlabelled version of the Cy5-dsRNA substrate (Figure 2A and Supplementary Table S4) , which resulted in exonuclease activity ( Figure 3E ) comparable to that observed with the Cy5 substrate ( Figure 3D ). Nsp14 is also an N7-guanine cap methyltransferase and the nsp10-14 fusion retains this methyltransferase activity (Supplementary Figure S2) .

The quantitative nature of the RiboGreen assay enabled us to determine the Michaelis-Menten constant (KM) of the nsp10-14 fusion protein for the unlabelled dsRNA substrate to be 66 nM (Supplementary Figure S3A and S3B). We then carried out a high-throughput screen to identify nsp14/10 exonuclease inhibitors from a custom library of over 5000 commercial compounds. The screen had a robust signal to noise ratio between positive and negative controls, and a mean Z' factor of 0.72, and we detected many compounds apparently able to reduce nsp14/10 exonuclease activity at both concentrations screened (Supplementary Figure S3C ). In the RiboGreen assay, fluorescence is highest at time zero of the exonuclease reaction, and cleavage of the substrate leads to reduced fluorescence signals ( Figure 2D or 3D as examples) . Thus, inhibition of exonuclease activity is expected to decrease the cleavage-dependent reduction in RiboGreen fluorescence. Based on this, to identify putative inhibitors of nsp14/10 exonuclease, we selected compounds that led to higher final fluorescence signals than control reactions. However, when we were validating these compounds, we found that many were auto-fluorescent in the wavelength range of RiboGreen fluorescence (Supplementary Figure S3D) . Because of this, we could not feasibly distinguish true hit compounds from auto-fluorescent false hits using this approach.

We decided to perform a second fluorescence-based high-throughput screen against the same library but using a different assay which utilises a different wavelength. For the new assay, we used an RNA duplex substrate with a 20-nucleotide 5' dU overhang, conjugated to a Cy3-quencher pair ( Figure 4A and Supplementary Table S4 ). Using this substrate, nucleolytic cleavage by nsp10-14 fusion protein released the Cy3 fluorophore strand from the quencher strand and produced fluorescent signal ( Figure 4A and 4B). When a DNA version of this substrate was used, only background levels of fluorescence were detected ( Figure 4B ). This indicated that, as expected, nsp10-14 is unable to cleave DNA substrates and that the fluorescence in reactions with the Cy3-dsRNA substrate is not due to unspecific factors such as temperature-dependent unwinding. When using this substrate, we were able to obtain kinetic data of the enzyme compared to the end-point information obtained when using our previous RiboGreen approach. We, thus, monitored fluorescence over time and titrated the substrate, which gave an estimated KM of 40 nM ( Figure 4C and 4D). The estimated KM was similar to our previous estimation using the RiboGreen assay (66 nM) (Supplementary Figure S3A and S3B), and therefore we decided to perform this second screen using 50 nM of substrate, as we did in the first screen. At 50 nM of substrate, we assessed nuclease activity over a range of enzyme concentrations and chose to do the reactions in the screen for 10 minutes with 0.5 nM of nsp10-14 fusion protein ( Figure 4E ).

As performed in the first screen, the drug library was screened at 1.25 µM and 3.75 µM.

First, nsp10-14 was incubated with the compounds for 10 min prior to the addition of the substrate, then fluorescent measurements were taken every minute for 10 min. The activity of nsp10-14 was defined as the slope of the reaction over the linear range. Again, the screen had a robust signal to noise ratio between positive and negative controls and a mean Z' factor of 0.86. The activity of nsp10-14 was normalised to the control wells without compounds (see Experimental Procedures). Both compound concentrations produced hits with residual activities less than 1 ( Figure 4F ). We considered compounds that reduced nsp10-14 activity below 80% in both concentrations, showed a Z score less than -5 ( Figure   4G ), and also showed some reduction in the first screen with RiboGreen detection. We also considered compounds that showed stronger inhibition in the higher dose in both screens, even if the absolute inhibition was not as strong as our initial cut-offs. We discounted some compounds for having a high aggregation index (>3 or known aggregators) [42] and for appearing in multiple screens (see accompanying manuscripts).

Taking the results from both screens into consideration, we tested 12 compounds in validation experiments (Supplementary Table S5 ). We returned to the gel-based assay with the Cy5-dsRNA substrate for validation. The nsp10-14 fusion protein was incubated with the hit compounds for 10 minutes prior to substrate addition as in the screens, and the reactions were stopped at 5 min instead of the usual 30 min reactions, to allow for the visualization of both the full-length RNA strand and the cleaved products. Two compounds inhibited nsp10-14 exonuclease activity in a concentration-dependent manner at both 5 µM and 25 µM: patulin and aurintricarboxylic acid (ATA) ( Figure 5A ). We also tested whether patulin To determine how specific patulin and ATA are to nsp10-14, we tested whether they inhibited other nucleases such as RNase A and benzonase. We titrated RNase A and benzonase to select enzyme concentrations that allowed us to visualise both full-length RNA and cleaved products in gel-based assays after 5 min (Supplementary Figure S4B) . Patulin did not inhibit RNase A or benzonase up to 50 µM, suggesting that it is not a general nuclease inhibitor ( Figure 5C ). Despite the fact that ATA has been described as a general inhibitor of nucleases and other DNA binding enzymes [43] , we observed only minor inhibition of RNase A and benzonase at 50 µM ATA ( Figure 5D ). In contrast, we observed inhibition of nsp10-14 from 5 µM ATA, indicating that it inhibits nsp10-14 at lower concentrations than it inhibits RNase A and benzonase ( Figure 5D ). Patulin showed an IC50 of 1.8 µM (95% CI 1.6 -2.1 µM) and ATA showed an IC50 of 10.3 µM (95% CI 8.6 -12.1 µM) ( Figure 5E and 5F and Supplementary Figures S4E and S4F) .

Importantly, in all the concentrations assayed, patulin and ATA do not quench Cy3 fluorescence (Supplementary Figure S4G and S4H ).

To explore if patulin and ATA could serve as antiviral drugs against SARS-CoV-2, we performed infectivity assays using VERO E6 cells in the presence of increasing concentrations of patulin and ATA. SARS-CoV-2 nsp14 exonuclease activity has been recently proposed to be essential for viral proliferation, and thus we expected that if patulin and ATA were able to inhibit nsp14 exonuclease also in cells, we would observe reduced viral infectivity [36] . Virus in VERO E6 cells 22 hours post-infection (MOI 0.5 PFU/cell) was detected by immunofluorescence with an antibody raised against the SARS-CoV-2 nucleocapsid (N) protein (see Experimental Procedures). Viral proliferation was reduced in the presence of patulin at ~ 5-10 µM ( Figure 6A and 6B). Above 10 µM, patulin decreased cell viability of cultured VERO E6 ( Figure 6A and 6B) . Similarly, we observed reduced viral proliferation in the presence of ATA in a dose-dependent manner from ~ 3-100 µM ( Figure   6C ). At the concentrations tested, ATA did not affect cell viability ( Figure 6C ).

Combining different antivirals is effective in treating viral infections and reducing treatment resistance [44] . To this end, we performed the SARS-CoV-2 infectivity assays in the presence of patulin or ATA in combination with the SARS-CoV-2 antiviral remdesivir. When combined, the dose-response curves of patulin and ATA were not shifted in response to a low dose (0.5 µM) of remdesivir, indicating that, under the conditions tested, these drugs do not synergise ( Figure 6D and 6E). We also performed the reciprocal experiment testing whether patulin would alter the remdesivir dose-response curve, but we did not observe any shift in the remdesivir curve in the presence of 3 µM or 5 µM patulin (Supplementary Figure   S5 ).

Previously, nsp14/nsp10 exonuclease activity had only been studied by monitoring cleavage of RNA substrates in gel-based assays using an excess of enzyme over substrate concentration [26, 36, 45, 46] . In this study, we have purified a fusion protein of nsp14 and nsp10 that shows ~ 100 fold higher exoribonuclease activity than the co-expressed or single nsp14 and nsp10 proteins. Further, we developed fluorescence-based assays for nsp14/10 exoribonuclease activity in solution, which are also scalable for high-throughput screens. We used these assays to screen for nsp14/10 exoribonuclease inhibitors among a custom chemical library of over 5000 commercial compounds and identified patulin and aurintricarboxylic acid (ATA) as inhibitors of SARS-CoV-2 nsp14/10 exonuclease.

The exoribonuclease (ExoN) domain of nsp14 is highly conserved among the nidoviruses that possess large genomes (>20 Kb), however, the function of ExoN for viral proliferation is still unclear. In addition to its proposed role as proofreader, nsp14/10 is thought to promote host innate immune evasion by cleaving dsRNA molecules and participate in viral genome recombination [37, 39, 47, 48] . ExoN is essential in SARS-CoV-2 [36] , so patulin and aurintricarboxylic acid (ATA), the new inhibitors of nsp14/10 exonuclease activity identified here, represent new tools to acutely inhibit ExoN activity during viral growth, which should be valuable for understanding the role of nsp14/10 ExoN during the viral life cycle. Also, considering the role of nsp14/10 in immune suppression, we speculate that even mild inhibition of nsp14/10 ExoN by patulin and ATA could lead to accumulation of highly immunogenic dsRNA molecules and promote strong immune antiviral responses.

A proofreader activity of nsp14 could reduce the effectiveness of nucleotide analogue chain terminators such as remdesivir by preventing their incorporation or removing them [49] .

Supporting this, ExoN mutants of murine hepatitis virus (MHV), a type of coronavirus, were shown to have 4.5-fold higher sensitivity to remdesivir treatment [12] . However, our results in VERO E6 cells did not show any synergy of patulin or ATA with remdesivir ( Figure 6C and 6D). Remdesivir acts as a delayed chain terminator where RNA synthesis stops about 3 nucleotides after its incorporation and perhaps nsp14/10 does not have access to remove it.

It would be interesting for future studies to examine whether patulin and ATA synergise with immediate chain terminators and to further explore how nsp14/10 might act as a proofreader.

ATA has been used as a positive control drug for nuclease inhibition due to its known roles as a general nuclease and DNA binding inhibitor [43, 50] . Indeed, ATA has recently been used as a control to inhibit nsp14/nsp10 exoribonuclease using a biochemical gel-based assay [51]. However, our results show that ATA inhibits nsp14/nsp10 exoribonuclease activity at much lower concentrations than the concentration needed to inhibit other nucleases such as RNase A and benzonase ( Figure 5D ), suggesting that ATA has specific activity towards SARS-CoV-2 nsp14/nsp10 compared to other nucleases. We cannot rule out the possibility that some of the antiviral activity of ATA is due to inhibition of other nucleases besides nsp14/10. ATA has been shown to inhibit replication of several other viruses including SARS-CoV-1 and Zika [52, 53] , and studies using cell culture and animal models have shown limited toxicity of ATA [53] [54] [55] . Further studies will be needed to understand the putative use of ATA for the inhibition of SARS-CoV-2 and treatment of COVID-19.

Patulin is a lactone mycotoxin produced by several species of Penicillium and Aspergillus, commonly found in foodstuffs such as rotting apples [56] . Patulin has antimicrobial effects and it has been shown to have cytotoxic, apoptotic and genotoxic effects in mammalian cells, including cancer cells [56-59]. While patulin does show some cellular toxicity in our assays, structural analogues of patulin were shown to have reduced toxicity compared to patulin in cell culture models [60], providing an opportunity to study alternative patulin-like molecules for the development of novel antiviral agents against coronaviruses. Also, considering that even mild inhibition of nsp14/10 exonuclease could have an effect on host immune responses, low and transient doses of patulin could also be considered. After some initially promising results in the early 20 th century, patulin was tested in a clinical trial for its ability to treat the common cold but found to be ineffective [61] . Since the time of this MRC trial, it has been shown that many viruses in addition to coronaviruses can cause the common cold, so it is likely that if patulin was effective only in treating coronavirus-based colds, the trial would not have uncovered it. It will be interesting for future studies to test patulin in the treatment of both COVID-19 and other coronavirus diseases.

The sequences of SARS-CoV-2 nsp14 and nsp10 (NCBI reference sequence NC_045512.2) were codon optimised for expression in E. coli using the GeneArt Gene Synthesis software (ThermoFisher scientific) and genes were ordered from GeneWiz (codon optimised DNA sequences in supplementary information). The HiFi DNA Assembly system (NEB) was used to build the plasmids to express individual, complex and fusion proteins (Supplementary Table S1 ice by addition of 0.33 mg/ml lysozyme followed by sonication (5 sec on/5 sec off at 35% for 3 min), and cell debris was cleared by centrifugation at 20,000 rpm for 30 min.

Plasmids SARS-CoV-2 nsp10-His-3xFlag (Addgene ID 169162), SARS-CoV-2 3xFlag-His-nsp5CS-nsp14 (Addgene ID 169163) and SARS-CoV-2 nsp14/nsp10-His-3xFlag (Addgene ID 169164) were expressed in baculovirus-infected Sf9 insect cells. The coding sequences of SARS-CoV-2 nsp10 and nsp14 (NCBI reference sequence NC_045512.2) were codon-optimised for S. frugiperda ordered from GeneArt (Thermo Fisher Scientific) (codon optimised DNA sequences can be found in supplementary information). Baculoviral expression vectors were generated using the biGBac vector system [63]. Nsp10 was subcloned into a modified pBIG1b vector containing a pLIB-derived polyhedrin expression cassette to contain a C- 

For substrate preparation, oligos i (unlabelled) and iii (unlabelled) (Supplementary Table S4) were diluted to 100 µM in RNase-free water, then mixed to a final concentration of 10 µM 

Substrate preparation was performed as for the RiboGreen assay, using oligos ii (Cy5) and

iii (unlabelled) (Supplementary Table S4 ). End-point nuclease assays were performed essentially as the RiboGreen assays except that reactions were stopped (1:1) with 2X sample buffer (98% Formamide, 10 mM EDTA). Samples were denatured at 95ºC for 2 min and loaded on 7M-urea polyacrylamide-1X TBE denaturing gels and run in 1x TBE running buffer at 180 V for 2 to 3 hours at RT before Cy5 fluorescence was visualised with an Amersham Imager 600, GE lifesciences.

For Cy3-substrates preparation, RNA oligos iv (Cy3) and v (quencher) or DNA oligos vi and vii were mixed at a 1:1.2 ratio with Cy3 oligo to 20 µM and Iowa Black RQ quencher oligo to 24 µM (Supplementary Table S4 

The methyltransferase activity of nsp10-14 was assayed by the detection of released SAH from the methyltransferase reaction. Released SAH was detected through the use of the commercially available EPIgeneous™ methyltransferase kit (CisBio Bioassays). Individual kit reagents were reconstituted according to the manufacturer's instruction. The methyltransferase reaction was conducted at room temperature in an 8 μl reaction volume with 10 nM nsp10-14, 1 μM Ultrapure SAM (CisBio), 0.14 mM GpppA RNA cap analogue (New England Biolabs) in reaction buffer consisting of HEPES-KOH pH 7.6, 150 mM NaCl, and 0.5 mM DTT. The reaction was started with the addition of nsp10-14 and was allowed to proceed for 20 minutes before quenching by the addition of 2 μl 5M NaCl to a final concentration of 1M.

Following quenching, 2 μl Detection Buffer 1 (CisBio) was immediately added to the reaction mixture. After 10 minutes, 4 μl of 16X SAH-d2 conjugate solution (CisBio) was added. 16X SAH-d2 was prepared by adding one part SAH-d2 to 15 parts Detection Buffer 2 (CisBio).

After 5 minutes, 4 μl of 1X α-SAH Tb Cryptate antibody solution was added to the reaction mixture. 1X α-SAH Tb Cryptate antibody solution was prepared by adding one part α-SAH Tb Cryptate antibody (CisBio) to 49 parts Detection Buffer 2 (CisBio).

Homogenous Time Resolved Fluorescence (HTRF) measurements were taken after 1 hour following α-SAH Tb Cryptate antibody addition on a Tecan Infinite M1000 Pro plate reader.

Readings were taken with a lag time of 60 μs after excitation at λ=337 nm. Readings were taken at emission wavelengths of λ=665nm and λ=620nm. The experimental HTRF ratio (HTRFexp) was then calculated as ratio of emission intensities: λ=665/λ=620. To reach the normalised HTRF ratio, HTRF ratio measurements were also taken of wells without enzyme (E0) and without SAH-d2 (d20), representing the maximum and minimum achievable HTRF values, respectively. The normalised HTRF ratio was then calculated as a linear transformation of the experimental HTRF ratio, the E0 ratio, and the d20 ratio:

High-throughput screening was performed using a custom compound collection assembled from commercial sources (Sigma, Selleck, Enzo, Tocris, Calbiochem, and Symansis). 2.5 or 7.5 nl of a 10 mM stock of the compounds dissolved in DMSO were arrayed and dispensed into square flat-bottom black 384-well plates containing 1 µl DMSO/well using an Echo 550 (Labcyte), before being sealed and stored at -80°C.

All steps and reagents were kept at room temperature (RT) during the day of the screen.

The morning of the screen all plates were moved from -80ºC to 4ºC. From there, plates were moved to RT 30 min before centrifuging and de-sealing. The RiboGreen screen was performed in three main steps which required the use of three independent XRD-384 Reagent Dispensers (FluidX Ltd.) each loaded with 16-channel tubing and set at high speed.

First, 10 µl of 2X enzyme mix (10 nM nsp10-14 fusion protein in 1X reaction buffer 1) was dispensed in columns 1 to 23 and incubated "Enzyme + drugs" for 10 min. After each dispensing, plates were centrifuged for <1 min at 4000 rpm. Second, 10 µl of 2X substrate mix (100 nM unlabelled dsRNA substrate in 1x reaction buffer 1) was dispensed in columns 2 to 24, and 10 µl reaction buffer 1 were pipetted by hand to control columns 1 and 24. After 

All steps and reagents were kept at RT during the days of the screen except the stock of enzyme mix that was kept in ice. The morning of the screen, all plates were moved from -80ºC to 4ºC. From there, plates were moved to room temperature for 30 min before centrifuging and de-sealing. This second screen was performed in two main steps which 

Screen data were analysed with custom MATLAB and R scripts. For the RiboGreen screen, normalised residual activity was calculated for each well, relative to the controls on that plate. The median background fluorescence, calculated from 8 wells containing no substrate, was subtracted from all wells, before normalisation using the formula:

where !"# is the median of 8 wells without enzyme (maximum signal), !$% is the median of 16 wells with no drug (minimum signal) and is the experimental value.

For the second Cy3/quencher-based screen, the slope of each reaction over the first 6 min was calculated by linear regression and then was normalised by dividing by the average of the control wells without drugs in each row of the plate.

In both screens, Z scores were then calculated for each experimental well.

where is the normalised experimental value, and "&& and "&& are the median and standard deviation of all 6106 normalised samples at that concentration respectively.

Z' factors were calculated for each plate to determine screen quality.

where '() and '() are the mean and standard deviation of the positive controls (no drugs) respectively, and %*+ and %*+ are the mean and standard deviation of the negative controls (no enzyme) respectively.

For the unlabelled dsRNA substrate, we calculated the initial velocity of the reactions 

Batches of the BetaCoV/England/02/2020 (Public Health England) strain of the SARS-CoV-2 virus were produced as in our accompanying manuscripts using VERO E6 cells. A 6-well plate plaque assay was then used to determine plaque forming units (PFU) per ml.

Viral infectivity assays were performed as in our accompanying manuscripts. Briefly, 96-well imaging plates (Greiner 655090) were seeded with VERO E6 cells and cultured overnight.

The next day, the media was replaced with fresh growth media, followed by addition of drug compounds. Finally, the cells were infected by SARS-CoV2 with a final MOI of 0.5 PFU/cell.

using Alexa488-labelled-CR3009 antibody and cellular DNA using DRAQ7 (ABCAM).

Imaging was carried out using an Opera Phenix (Perkin Elmer) and fluorescent areas and intensity calculated using the Phenix-associated software Harmony (Perkin Elmer).

Alexa488/N intensities were normalised to DRAQ7/DNA, and to vehicle only samples.

All data associated with this paper will be deposited in FigShare 

SARS-CoV-2 infectivity assays in VERO E6 assay performed as in Figure 5A with 

species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Coronaviruses and the cardiovascular system: acute and longterm implications

Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine

Human Erythroid Progenitors Are Directly Infected by SARS-CoV-2: Implications for Emerging Erythropoiesis in Severe

Characteristics of SARS-CoV-2 and COVID-19

Broad-spectrum coronavirus antiviral drug discovery

Evaluating the impact of stay-at-home orders on the time to reach the peak burden of Covid-19 cases and deaths: does timing matter?

Origin and evolution of pathogenic coronaviruses

Coronavirus as a possible cause of severe acute respiratory syndrome

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

Remdesivir for the Treatment of Covid-19 -Final Report

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

Coronavirus biology and replication: implications for SARS-CoV-2

The coding capacity of SARS-CoV-2

Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus

Discovery of an RNA virus 3'->5' exoribonuclease that is critically involved in coronavirus RNA synthesis

Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase

In vitro reconstitution of SARS-coronavirus mRNA cap methylation

Structural basis and functional analysis of the SARS coronavirus nsp14-nsp10 complex

The proofreading domain of Escherichia coli DNA polymerase I and other DNA and/or RNA exonuclease domains

Exoribonuclease superfamilies: structural analysis and phylogenetic distribution

RNA 3'-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex

Nidovirales: evolving the largest RNA virus genome

High fidelity of murine hepatitis virus replication is decreased in nsp14 exoribonuclease mutants

Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics

Proofreading-Deficient Coronaviruses Adapt for Increased Fitness over Long-Term Passage without Reversion of Exoribonuclease-Inactivating Mutations

The Curious Case of the Nidovirus Exoribonuclease: Its Role in RNA Synthesis and Replication Fidelity

Mutations in coronavirus nonstructural protein 10 decrease virus replication fidelity

Infidelity of SARS-CoV Nsp14-Exonuclease Mutant Virus Replication Is Revealed by Complete Genome Sequencing

One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities

Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription Complex Reveals an Intermediate State in Cap Synthesis

The Enzymatic Activity of the nsp14 Exoribonuclease Is Critical for Replication of MERS-CoV and SARS-CoV-2

Mutagenesis of Coronavirus nsp14 Reveals Its Potential Role in Modulation of the Innate Immune Response

Murine Hepatitis Virus nsp14 Exoribonuclease Activity Is Required for Resistance to Innate Immunity

The coronavirus proofreading exoribonuclease mediates extensive viral recombination

Drug repositioning: identifying and developing new uses for existing drugs

Rapid repurposing of drugs for COVID-19

An Aggregation Advisor for Ligand Discovery

Use of aurintricarboxylic acid as an inhibitor of nucleases during nucleic acid isolation

Drug repurposing screens and synergistic drug-combinations for infectious diseases

Coronavirus Nsp10, a critical co-factor for activation of multiple replicative enzymes

New targets for drug design: Importance of nsp14/nsp10 complex formation for the 3'-5' exoribonucleolytic activity on SARS-CoV-2. bioRxiv

We thank the Crick high-throughput screen (HTS) science technology platform (STP) for providing the chemical library and for help with screen design and analysis and are grateful to MRC Reagents and Services (https://mrcppureagents.dundee.ac.uk/) for providing DU70487 DNA construct for nsp14. We thank the Fermentation unit of the Crick Structural biology STP for large scale protein expression. We thank David McClure for help with screen analysis. We thank Anne Early for ordering supplies and hit compounds. We thank Chris Smith for help with initial screen design and concepts. This work was supported by the